How does 7Z6's PB Ratio compare to its peers?

7Z6 is expensive based on its Price-To-Book Ratio (3.8x) compared to the peer average (1.7x).

How does 7Z6's PB Ratio compare vs other companies in the DE Biotechs Industry?

7Z6 is expensive based on its Price-To-Book Ratio (3.8x) compared to the European Biotechs industry average (2.5x).

What is 7Z6's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 7Z6's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 7Z6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 7Z6's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

7Z6 Stock Overview

A biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer. More details

7Z6 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 109.25% per year

Earnings have grown 17.6% per year over the past 5 years

Risk Analysis

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (SEK0)

Does not have a meaningful market cap (€83M)

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Coegin Pharma AB Competitors

co.don

XTRA:CNW

€6.5m

2invest

XTRA:2INV

€67.3m

Medigene

XTRA:MDG1

€15.5m

Heidelberg Pharma

XTRA:HPHA

€111.4m

Price History & Performance

Summary of share price highs, lows and changes for Coegin Pharma
Historical stock prices
Current Share Price	SEK 0.32
52 Week High	SEK 0.74
52 Week Low	SEK 0.31
Beta	0.97
1 Month Change	0%
3 Month Change	-1.84%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-47.54%

Recent updates

Shareholder Returns

	7Z6	DE Biotechs	DE Market
7D	0%	1.9%	1.4%
1Y	n/a	-9.8%	9.1%

Return vs Industry: Insufficient data to determine how 7Z6 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 7Z6 performed against the German Market.

Price Volatility

Is 7Z6's price volatile compared to industry and market?
7Z6 volatility
7Z6 Average Weekly Movement	9.8%
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 7Z6's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 7Z6's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2005	1	Jens Eriksson	coeginpharma.com

Coegin Pharma AB, a biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer. Its products include AVX001 GEL drug candidate, which is in phase 2 clinical study for the treatment of actinic keratosis and in phase 1 clinical study for the treatment of basal cell carcinoma; AVX420 drug candidate in preclinical study for the indication of leukemia; FOL026, a peptide-based drug in preclinical study for the prevention of cardiovascular complications in diabetes; AVX420/FOL026 therapy in preclinical study for the treatment of kidney and liver fibrosis; and FOL005 for the treatment of stimulation of hair growth. The company was founded in 2005 and is based in Lund, Sweden.

Coegin Pharma AB Fundamentals Summary

How do Coegin Pharma's earnings and revenue compare to its market cap?
7Z6 fundamental statistics
Market cap	€7.20m
Earnings (TTM)	-€2.27m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.2x

P/E Ratio

Is 7Z6 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7Z6 income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 16.00k
Gross Profit	-SEK 16.00k
Other Expenses	SEK 25.99m
Earnings	-SEK 26.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.28
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 7Z6 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/06 06:07
End of Day Share Price	2024/11/25 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Coegin Pharma AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kevin Sule	Redeye

Coegin Pharma BST:7Z6 Stock Report